ClinicalTrials.gg
Enrolling by invitationNCT06394908ReMIUS-UUpdated Aug 20, 2025

Registry of MIUS for Urolithiasis (ReMIUS-U)

An observational study in Urolithiasis, Stone, Kidney and Stone Ureter, sponsored by Marmara University. Enrolling by invitation at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2025-08-20.

Primary conditionKidney CalculiRegistry: UrolithiasisReclassifiedWhy we changed it
Registry
Urolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Calculi
Why
  1. The study's listed conditions name Kidney Calculi, a narrower term within Urolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Marmara University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10,000
Sex
All
01

Study summary

The purpose of this registry is to collect data on patients who have undergone minimally invasive treatments for urinary system stone disease, including percutaneous nephrolithotomy (PCNL), shock wave lithotripsy (SWL), semi-rigid ureterorenoscopy (URS), and flexible ureterorenoscopy (F-URS).

Read the detailed description

In this project, the Minimally Invasive Urology Association urolithiasis study group aimed to collect the data of adult and pediatric urinary system stone patients treated with PCNL, SWL, URS, and F-URS in a non-randomized, observational, and prospective manner. The registry was to be conducted multi-center in Turkey.

In this project, Excel files were created and shared via Google Drive with the responsible physicians at the centers to be included in the study. Each parameter was prepared in an explanatory manner and can be readily filled out by physicians familiar with these methods. The ability to examine and modify existing data will be restricted to the worker and the database administrator. Patients' identities will not be revealed in the registry.

The collected data are summarized in three sections under the major headings below;

  1. Demographics and preoperative information; Patient, disease, and treatment method demographic data, such as age, gender, height, weight, previous diseases, medications used, location, size, and hardness of urinary tract stones, the side of the stone, and the methods used for diagnosis, will be prospectively recorded for patients whose consent was obtained.
  2. Data during the operation; The duration of the operation as well as the devices and methods utilized will be recorded.
  3. In the postoperative period, post-treatment findings, such as stone-free status and post-treatment complications, will be documented.

A separate application to the ethics committee will be submitted for each study on the subject that will be created in the future from the multi-center, prospectively recorded data pool and on the subject that will be investigated.

02

Conditions studied

  • Urolithiasis
  • Stone, Kidney
  • Stone Ureter
  • Complication of Surgical Procedure

Browse trials for

Keywords

  • Prospective studies
  • Registries
  • Urolithiasis
03

In context

Kidney Calculi Reclassified

509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 160 across 96 observational studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Marmara University is the lead sponsor of 599 studies on the registry; 138 are open to participants now.

Compared within Kidney Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who receive urolithiasis treatment without contraindication

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To have a medical indication for urolithiasis
  • Complete data of treatment and follow-up course
  • Patients with consent
  • Patients > 18 years-old
  • Patients \< 18 years-old

Exclusion criteria

Exclusion Criteria:

  • Missing data
  • Patients without consent
  • Not to have a medical indication for urolithiasis treatment
  • To have a for urolithiasis treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Operative durations of each treatment technique (PCNL, SWL, URS, F-URS)

    The duration of the operation time

    Time frame: Operation/procedure day

  2. Operative radiation dosage of each treatment technique (PCNL, SWL, URS, F-URS)

    X-ray dosage

    Time frame: Operation/procedure day

  3. Operative results of each treatment technique (PCNL, SWL, URS, F-URS)

    The duration of the laser time

    Time frame: Operation/procedure day

  4. Postoperative results

    Postoperative estimated glomerular filtration rate (CKD Epidemiology Collaboration (CKD-EPI) equation) (mL/min/1.73 m2)

    Time frame: immediately after procedure

  5. Rate of postoperative complication

    Abnormal clinical and laboratory findings that may be seen after surgery and require additional intervention, treatment, or follow-up

    Time frame: up to 3 months, postoperatively

  6. Follow-up

    Follow-up results of patients for recurrence of disease of residual stones, if any reoperation records.

    Time frame: up to 10 years

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06394908
Lead sponsor
Marmara University
Collaborators
Samsun Education and Research Hospital, Gazi University, Koç University, Baskent University, Cukurova University, Ondokuz Mayıs University, Muğla Sıtkı Koçman University, Necmettin Erbakan University, Alanya Alaaddin Keykubat University, Dokuz Eylul University, Hitit University
Responsible party
Yiloren Tanidir (Associate professor, Marmara University) — Principal investigator
First posted
May 1, 2024
Start date
May 10, 2023
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Aug 20, 2025

Study contacts

yiloren tanidir, Assoc.Prof
study chair · Marmara University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion